'Primary endpoints' diaporamas de présentation

Department of Thoracic/Head & Neck

Management of EGFR-Mutant NSCLC Resistant to EGFR-TKI therapy. Anne S. Tsao, M.D. Director, Mesothelioma Program Director, Thoracic Chemo-XRT Program. Associate Professor. The University of Texas. Department of Thoracic/Head & Neck. MD ANDERSON. Medical Oncology. CANCER CENTER.

790 views • 63 slides

The Role of Cytogenetics in Elderly patients with Myeloma

The Role of Cytogenetics in Elderly patients with Myeloma Dr Faith Davies Cancer Research UK Senior Cancer Fellow Centre for Myeloma Research Divisions of Molecular Pathology, Cancer Therapeutics and Clinical Studies Royal Marsden Hospital and The Institute of Cancer Research London.

827 views • 57 slides

Multiple Primary Endpoints in Clinical Trials

Multiple Primary Endpoints in Clinical Trials. Michael J. Brown Robb J. Muirhead Pfizer Global Research and Development BASS XI November 2, 2004: Savannah, GA. Outline. Two Presentations in one Multiple Endpoint Issues (MB) Description Endpoints Measuring Disease

879 views • 54 slides

Investigator and Study Coordinator Responsibilities: A Focus on FDAs Final Guidance

Investigator and Study Coordinator Responsibilities: A Focus on FDAs Final Guidance . Kimberly Summers, PharmD Deputy ACOS for Research South Texas Veterans Health Care System Research & Development Service. FDA Responsibilities.

870 views • 43 slides

Analysis of Multiple End Points in Clinical trials

460 views • 27 slides

Results from the Rheos Pivotal Trial Baroreflex Activation Therapy Sustainably Lowers Blood Pressure in Patients with R

Results from the Rheos Pivotal Trial Baroreflex Activation Therapy Sustainably Lowers Blood Pressure in Patients with Resistant Hypertension. John Bisognano , Domenic Sica , Mitra Nadim, Luis Sanchez, George Bakris, On Behalf of the Rheos Pivotal Trial Investigators.

498 views • 19 slides

R. Sridhara, G. Chen, K. He, G.Y.H. Chi Division of Biometrics 1 OB, OPaSS, CDER, FDA

316 views • 19 slides

Hisao Ogawa 1 , Shokei Kim-Mitsuyama 2 , Tomio Jinnouchi 3 , Hideaki Jinnouchi 3 , Kunihiko Matsui 4 and Kikuo Arakawa

Effect of High-dose Angiotensin II Receptor Blocker (ARB) Monotherapy versus ARB plus Calcium Channel Blocker Combination on Cardiovascular Events in Japanese Elderly High-risk Hypertensive Patients (OSCAR): a Randomized Trial.

617 views • 18 slides

First line therapeutic options for HER2 positive metastatic breast cancer

First line therapeutic options for HER2 positive metastatic breast cancer. Harold Burstein, MD Assistant Professor of Medicine Dana-Farber Cancer Institute Boston , MA . Trastuzumab in advanced/metastatic breast cancer. 1. Slamon et al, N Engl J Med. 2001;344:783-92.

438 views • 17 slides

Prof. Sverre E. Kjeldsen, MD, PhD Past-President European Society of Hypertension

The 4th International Conference FIXED COMBINATION, Paris, December 3, 2011. Accomplish Update: Fixed Dose RAAS Blocker and CCB in Prevention of Endpoints in the Treatment of Hypertension. Prof. Sverre E. Kjeldsen, MD, PhD Past-President European Society of Hypertension

376 views • 15 slides

Background

Whitney Jones, PharmD Candidate 1 ; LeAnn B. Norris, PharmD, BCPS 2 ; P. Brandon Bookstaver, PharmD, BCPS 2 ; Richard Schulz, PhD 2 1 University of South Carolina College of Pharmacy, Columbia, SC; 2 South Carolina College of Pharmacy, USC Campus, Columbia, SC.

332 views • 12 slides

Comparison of NNRTI vs PI/r

Comparison of NNRTI vs PI/r. EFV vs LPV/r vs EFV + LPV/r ACTG A5142 EFV vs LPV/r Mexican Study NVP vs ATV/r ARTEN EFV vs ATV/r ACTG A5202. A5142. ACTG A5142: [(EFV vs LPV/r) + 2 NRTIs] vs EFV + LPV/r. Design. Randomisation* 1:1:1 Open-label. W96.

360 views • 11 slides